TELADOC HEALTH, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.26 USD | -1.96% |
|
-4.69% | -47.68% |
| May. 21 | JPMorgan Adjusts Teladoc Price Target to $16 From $19, Maintains Neutral Rating | MT |
| Apr. 29 | Truist Securities Cuts Teladoc's Price Target to $15 From $17, Maintains Hold Rating | MT |
Financials (USD)
| Sales 2024 * | 2.66B | Sales 2025 * | 2.76B | Capitalization | 1.95B |
|---|---|---|---|---|---|
| Net income 2024 * | -177M | Net income 2025 * | -110M | EV / Sales 2024 * | 0.84 x |
| Net Debt 2024 * | 297M | Net Debt 2025 * | 61.18M | EV / Sales 2025 * | 0.73 x |
| P/E ratio 2024 * |
-10.7
x | P/E ratio 2025 * |
-17.1
x | Employees | 5,208 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.22% |
More Fundamentals
* Assessed data
More news
Latest transcript on Teladoc Health, Inc.
More recommendations
More press releases
| 1 day | -1.61% | ||
| 1 week | -4.35% | ||
| Current month | -11.25% | ||
| 1 month | -15.50% | ||
| 3 months | -25.02% | ||
| 6 months | -37.42% | ||
| Current year | -47.49% |
1 week
11.27
12.04
1 month
11.2713.47
Current year
11.2722.54
1 year
11.2730.41
3 years
11.27174.32
5 years
11.27308.00
10 years
9.08308.00
| Managers | Title | Age | Since |
|---|---|---|---|
Mala Murthy
CEO | Chief Executive Officer | 60 | 19-06-23 |
Jeff Nadler
CTO | Chief Tech/Sci/R&D Officer | - | 11-01-31 |
Nikolaos Nanis
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
David Snow
CHM | Chairman | 69 | 14-01-31 |
Sandra Fenwick
BRD | Director/Board Member | 73 | 20-11-18 |
David Shedlarz
BRD | Director/Board Member | 75 | 16-09-18 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 4.31% | 1 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-28 | 11.26 | -1.92% | 2 306 620 |
| 24-05-24 | 11.48 | +0.26% | 4,399,903 |
| 24-05-23 | 11.45 | -3.94% | 4,826,526 |
| 24-05-22 | 11.92 | +0.76% | 3,589,360 |
| 24-05-21 | 11.83 | -3.82% | 4,693,789 |
Delayed Quote Nyse, May 28, 2024 at 01:20 pm EDT
More quotes
Teladoc Health, Inc. provides virtual healthcare services. The Company operates through two segments: Teladoc Health Integrated Care (Integrated Care) and BetterHelp. The Integrated Care segment includes a suite of global virtual medical services including general medical, expert medical services, specialty medical, chronic condition management, mental health, and enabling technologies and enterprise telehealth solutions for hospitals and health systems. Services in this segment are distributed primarily on a business-to-business (B2B) basis. The BetterHelp segment primarily consists of its direct-to-consumer (D2C) mental health platform. The online counseling and therapy services are provided via its network of over 40,000 licensed clinicians leveraging its platform for Web, mobile app, phone, and text-based interactions. Its Teladoc Health family of brands, including Teladoc and BetterHelp, deliver access to advice and resolution for an array of healthcare needs.
Calendar
2024-07-22
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
HOLD
Number of Analysts
27
Last Close Price
11.48
USD
Average target price
16.95
USD
Spread / Average Target
+47.67%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -47.49% | 1.95B | |
| +78.57% | 584M | |
| +10.83% | 485M | |
| -70.70% | 128M | |
| -28.06% | 91.48M |
- Stock Market
- Equities
- TDOC Stock
